Reprogramming T Cells Inside the Body Could Make CAR-T Cancer Therapy Cheaper and More Accessible

CAR T cell therapy has changed the outlook for several blood cancers, and seven products have received FDA approval. Yet most patients cannot easily access it. Current products require collecting a patient's T cells, engineering them in a specialized facility, and reinfusing them, which is expensive, slow, and logistically demanding.

This review from Trends Cancer examines a different approach: engineering CAR T cells inside the body. Rather than manufacturing cells outside the patient, delivery vehicles carry the genetic instructions for a CAR directly to T cells in vivo. The authors survey both viral and nonviral delivery platforms, drawing on preclinical and early clinical data.

Based on the abstract, early clinical studies show these approaches can be safe and therapeutically active. The authors suggest in vivo engineering could simultaneously improve potency, reduce costs, and broaden accessibility compared with current ex vivo manufacturing.

The review emphasizes that important questions remain. These include how durable the responses are over the long term, how the delivery method interacts with host biology, and which disease indications are best matched to each delivery approach. Answers will shape how the field matures.

Several caveats apply. Only the abstract was available, so specific data, platforms, and clinical outcomes cannot be detailed here. The clinical evidence is described as early. One author is a cofounder and equity holder in Kelonia Therapeutics, a company in this space, and holds related patents, which readers should consider when weighing the review's perspective.